pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-3940 |
Genomic Coordinates | chr19: 6416410 - 6416511 |
Description | Homo sapiens miR-3940 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-3940-3p | |||||||||||||||||||||||||||||||||
Sequence | 57| CAGCCCGGAUCCCAGCCCACUU |78 | |||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||
Experiments | Illumina | DRVs in miRNA |
|
|||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | C21orf2 | ||||||||||||||||||||
Synonyms | LRRC76, RDMS, SMDAX, YF5/A2 | ||||||||||||||||||||
Description | chromosome 21 open reading frame 2 | ||||||||||||||||||||
Transcript | NM_004928 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on C21orf2 | |||||||||||||||||||||
3'UTR of C21orf2 (miRNA target sites are highlighted) |
>C21orf2|NM_004928|3'UTR 1 CCGCAGGACCTGAACGCCGCTCCAGCCTCCACGGGGACCCCAGCGTCTTCCCCAGCCCCCGGGAGCTGGAGGGTGGCTGC 81 CATGGCCGCAGCCCCGGCCCCACACAAAAGCCTCCCCGGTTTGCCACATCGGCCGAGGGCAGGAGTGGGTGTTAGGTACT 161 GGCTAACCGGGGCGGTGGAGATGCCTGTCTACACCAGTCCTGTCCCCAGGACTCCCCTTCTGTGGTCTGGAGGTTCTAGG 241 CTGGCCTGGGCTCTTAAAGGGAGGATTTTGCAGGCTGTCCTCCCTAATAAAAGATTTTCCCAAGGTTGATCTGGAGGTGA 321 CGTTTCCCAAGGCATGGTTGTGACAGTCTTCCTGAAAGCAAGGGCCGTTTCTCCACAGAATGAGGAGGTCTTCACGGATG 401 GCTTTGCCGATTCCAGCCCTTGGTCCTTGGATAGATTTCTGTTGGGCAAGGGAGACTTCGAGAATGCTGGCACCCATAGC 481 GACATCTGCCCTGAGCTGCTCAGCAGGCAGGCAGCAGCCTCCCGCACCCATGGGAGAGAGTTTTGTTTTCTTGGCCGGGC 561 TGGGCAGGTGCGCCTTCCTTTCTCTCTCCTGTGAAGAACTGCAGGAGGGCCCTCAGCTGTGAGGTTGTGGATGAACAGGC 641 CTGTTCGCCCTGGGGTCCGGGCCTGGCACAGGAAGCAGCTAGACTAGGGGAGTCCTTGGAGCATCTGAGAGGGGTTTTCT 721 TTCCTCTGGGAAGAGTCGCAAGTCTTATGAGGATGCCACAATCTGGGCAGTGACCCGTGGCCCTGGGGACCTTCCTAGTG 801 CCCCCCAAAACCAAGGAAGCATTCACGTGAGATGGGGAGTCAGCCTTCCAGCTGGTGTGTAGGAAAGCCAGGTCCCTGGG 881 CCCTTGTCCCATGTGGGGTTGAGATCCAGATCTCCATGAGATATTCCCATCCTCCGCCGAGCGGTGATGCGTGACCGTGT 961 GTGCAGGCCGCTGTTCTCCCAAGCTCGGGGCCATGCCGTGCCACCGTCACCAGAGCCAGCTGCAGCACTGGGGCAGCCAC 1041 TGTCGCCGGACTTGGGGAAGCCCAGGGTGAAGACAGTCACTCATCCGTGCAAGCTCTCCAGAAGGGATGCAAGCTCTCCA 1121 GAAGGGGTGTGATCTCTGAGCAGTGGGGAGTGGAGTCACCACTCGGGACATAGAGGGTGGACAGTTCAGGCCTGTGTCTG 1201 CCTCCTTGGGACTGTGGAGTGGGTGCCCTCAGTAAAGCGCTTTGTTGGAATGGTAAAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | LCL-BAC | ||||||
Disease | MIMAT0018356 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1020023. RNA binding protein: AGO2. Condition:EBV B95-8-infected
... - Skalsky RL; Corcoran DL; Gottwein E; Frank et al., 2012, PLoS pathogens. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Skalsky RL; Corcoran DL; Gottwein E; Frank et al. - PLoS pathogens, 2012
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus linked to a number of B cell cancers and lymphoproliferative disorders. During latent infection, EBV expresses 25 viral pre-microRNAs (miRNAs) and induces the expression of specific host miRNAs, such as miR-155 and miR-21, which potentially play a role in viral oncogenesis. To date, only a limited number of EBV miRNA targets have been identified; thus, the role of EBV miRNAs in viral pathogenesis and/or lymphomagenesis is not well defined. Here, we used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) combined with deep sequencing and computational analysis to comprehensively examine the viral and cellular miRNA targetome in EBV strain B95-8-infected lymphoblastoid cell lines (LCLs). We identified 7,827 miRNA-interaction sites in 3,492 cellular 3'UTRs. 531 of these sites contained seed matches to viral miRNAs. 24 PAR-CLIP-identified miRNA:3'UTR interactions were confirmed by reporter assays. Our results reveal that EBV miRNAs predominantly target cellular transcripts during latent infection, thereby manipulating the host environment. Furthermore, targets of EBV miRNAs are involved in multiple cellular processes that are directly relevant to viral infection, including innate immunity, cell survival, and cell proliferation. Finally, we present evidence that myc-regulated host miRNAs from the miR-17/92 cluster can regulate latent viral gene expression. This comprehensive survey of the miRNA targetome in EBV-infected B cells represents a key step towards defining the functions of EBV-encoded miRNAs, and potentially, identifying novel therapeutic targets for EBV-associated malignancies.
LinkOut: [PMID: 22291592]
|
CLIP-seq Support 1 for dataset GSM1020023 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | LCL-BAC / EBV B95-8-infected, 4-thiouridine, RNase T1 |
Location of target site | ENST00000339818.4 | 3UTR | UUGGCCGGGCUGGGC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22291592 / GSE41437 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
42 hsa-miR-3940-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT118010 | BLOC1S3 | biogenesis of lysosomal organelles complex 1 subunit 3 | 2 | 6 | ||||||||
MIRT268170 | POU2F1 | POU class 2 homeobox 1 | 2 | 2 | ||||||||
MIRT289461 | BIRC5 | baculoviral IAP repeat containing 5 | 2 | 4 | ||||||||
MIRT409766 | HRH2 | histamine receptor H2 | 2 | 2 | ||||||||
MIRT452070 | ZNF585B | zinc finger protein 585B | 2 | 8 | ||||||||
MIRT458519 | GSG2 | histone H3 associated protein kinase | 2 | 6 | ||||||||
MIRT458657 | SGPP2 | sphingosine-1-phosphate phosphatase 2 | 2 | 2 | ||||||||
MIRT465898 | TMEM41B | transmembrane protein 41B | 2 | 2 | ||||||||
MIRT469877 | PURB | purine rich element binding protein B | 2 | 4 | ||||||||
MIRT470462 | PPP1R11 | protein phosphatase 1 regulatory inhibitor subunit 11 | 2 | 2 | ||||||||
MIRT481439 | ASB6 | ankyrin repeat and SOCS box containing 6 | 2 | 2 | ||||||||
MIRT482643 | RPL18A | ribosomal protein L18a | 2 | 2 | ||||||||
MIRT486034 | CYTH1 | cytohesin 1 | 2 | 2 | ||||||||
MIRT486423 | RXRA | retinoid X receptor alpha | 2 | 2 | ||||||||
MIRT490254 | MFI2 | melanotransferrin | 2 | 2 | ||||||||
MIRT491213 | MLLT1 | MLLT1, super elongation complex subunit | 2 | 4 | ||||||||
MIRT492849 | NRGN | neurogranin | 2 | 2 | ||||||||
MIRT492995 | NAV1 | neuron navigator 1 | 2 | 2 | ||||||||
MIRT493423 | KDM6B | lysine demethylase 6B | 2 | 2 | ||||||||
MIRT495331 | MON1B | MON1 homolog B, secretory trafficking associated | 2 | 2 | ||||||||
MIRT496865 | C21orf2 | chromosome 21 open reading frame 2 | 2 | 2 | ||||||||
MIRT498435 | EHD4 | EH domain containing 4 | 2 | 2 | ||||||||
MIRT514977 | CCBE1 | collagen and calcium binding EGF domains 1 | 2 | 2 | ||||||||
MIRT525668 | KXD1 | KxDL motif containing 1 | 2 | 2 | ||||||||
MIRT564349 | AKR1B10 | aldo-keto reductase family 1 member B10 | 2 | 2 | ||||||||
MIRT565241 | TRAF6 | TNF receptor associated factor 6 | 2 | 2 | ||||||||
MIRT573209 | C12orf49 | chromosome 12 open reading frame 49 | 2 | 2 | ||||||||
MIRT635215 | ZNF286A | zinc finger protein 286A | 2 | 4 | ||||||||
MIRT638282 | SH2B3 | SH2B adaptor protein 3 | 2 | 2 | ||||||||
MIRT650230 | SIGLEC9 | sialic acid binding Ig like lectin 9 | 2 | 2 | ||||||||
MIRT665256 | ZNF286B | zinc finger protein 286B | 2 | 2 | ||||||||
MIRT665833 | TIMELESS | timeless circadian clock | 2 | 2 | ||||||||
MIRT666891 | POLA2 | DNA polymerase alpha 2, accessory subunit | 2 | 2 | ||||||||
MIRT667161 | NRXN3 | neurexin 3 | 2 | 2 | ||||||||
MIRT679853 | GPR75 | G protein-coupled receptor 75 | 2 | 2 | ||||||||
MIRT680747 | CA5B | carbonic anhydrase 5B | 2 | 2 | ||||||||
MIRT682071 | QPCTL | glutaminyl-peptide cyclotransferase like | 2 | 2 | ||||||||
MIRT695801 | SCUBE3 | signal peptide, CUB domain and EGF like domain containing 3 | 2 | 2 | ||||||||
MIRT705465 | ATG9A | autophagy related 9A | 2 | 2 | ||||||||
MIRT714270 | LTBP2 | latent transforming growth factor beta binding protein 2 | 2 | 2 | ||||||||
MIRT716392 | NPAS1 | neuronal PAS domain protein 1 | 2 | 2 | ||||||||
MIRT718443 | RAB11B | RAB11B, member RAS oncogene family | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|